RT Book, Section
A1 White, Christopher J.
A1 Tafur-Soto, Jose David
A2 Samady, Habib
A2 Fearon, William F.
A2 Yeung, Alan C.
A2 King III, Spencer B.
SR Print(0)
ID 1146604656
T1 Renal Artery Angioplasty and Stenting
T2 Interventional Cardiology, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071820363
LK accesscardiology.mhmedical.com/content.aspx?aid=1146604656
RD 2024/04/25
AB Clinical  benefit  from  any  revascularization  procedure  will  be  the  net  gain  due  to  reperfusion  of  the  ischemic  organ  balanced  against  the  risk  of  a  procedural  complication.  The  same  is  true  for  renal  artery  ischemia  caused  by  atherosclerotic  or,  less  commonly,  fibromuscular  dysplasia  (FMD)  lesions  (Fig.  52-1).  Recent  clinical  trials  have  attempted  to  determine  the  benefit  of  revascularization  but  have  been  seriously  hampered  by  difficulty  in  defining  a  threshold  for  an  ischemia  producing  renal  artery  stenosis  (RAS).